Aytu Biopharma, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
AYTU Biopharma, Inc. has filed definitive additional proxy soliciting materials with the U.S. Securities and Exchange Commission.
NASDAQ
Aytu BioPharma, Inc. announces its 2026 annual meeting of stockholders to be held on December 10, 2025, detailing proposals for director elections, auditor ratification, and executive compensation.
NASDAQ
Aytu BioPharma has filed a definitive proxy statement with the SEC.
NASDAQ
DEF: Aytu BioPharma Seeks Stockholder Approval for Equity Incentive Plan Amendment at 2025 Annual Meeting
Aytu BioPharma is holding its annual meeting on May 21, 2025, seeking stockholder approval for several proposals, including an amendment to the 2023 Equity Incentive Plan to increase the number of shares reserved for issuance.
NASDAQ
Aytu BioPharma, Inc. has filed a definitive proxy statement with the SEC.
NASDAQ
Aytu BioPharma will hold its annual meeting of stockholders on June 26, 2024, to elect directors, ratify the appointment of its accounting firm, and conduct an advisory vote on executive compensation.